Literature DB >> 20808223

Hormonal approaches to male contraception.

Christina Wang1, Ronald S Swerdloff.   

Abstract

PURPOSE OF REVIEW: Condoms and vasectomy are male-controlled family planning methods but suffer from limitations in compliance (condoms) and limited reversibility (vasectomy); thus many couples desire other options. Hormonal male contraceptive methods have undergone extensive clinical trials in healthy men and shown to be efficacious, reversible and appear to be well tolerated. RECENT
FINDINGS: The success rate of male hormonal contraception using injectable testosterone alone is high and comparable to methods for women. Addition of progestins to androgens improved the rate of suppression of spermatogenesis. Supported by government or nongovernment organizations, current studies aim to find the best combination of testosterone and progestins for effective spermatogenesis suppression and to explore other delivery methods for these hormones. Translation of these advances to widespread use in the developed world will need the manufacturing and marketing skills of the pharmaceutical industry. Availability of male contraceptives to the developing world may require commitments of governmental and nongovernmental agencies. In a time when imbalance of basic resources and population needs are obvious, this may prove to be a very wise investment.
SUMMARY: Male hormonal contraception is efficacious, reversible and well tolerated for the target population of younger men in stable relationships. Suppression of spermatogenesis is achieved with a combination of an androgen and a progestin. Partnership with industry will accelerate the marketing of a male hormonal contraceptive. Research is ongoing on selective androgen and progesterone receptor modulators that suppress spermatogenesis, minimize potential adverse events while retaining the androgenic and gonadotropin suppressive actions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20808223      PMCID: PMC3078035          DOI: 10.1097/MOU.0b013e32833f1b4a

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  50 in total

1.  Azoospermia: virtual reality or possible to quantify?

Authors:  T G Cooper; B Hellenkemper; J Jonckheere; N Callewaert; A J Grootenhuis; W M Kersemaekers; A Leung; C Wang
Journal:  J Androl       Date:  2006-04-05

Review 2.  Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit.

Authors:  Michael L Mohler; Casey E Bohl; Amanda Jones; Christopher C Coss; Ramesh Narayanan; Yali He; Dong Jin Hwang; James T Dalton; Duane D Miller
Journal:  J Med Chem       Date:  2009-06-25       Impact factor: 7.446

3.  Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada.

Authors:  A H Wu; A S Whittemore; L N Kolonel; E M John; R P Gallagher; D W West; J Hankin; C Z Teh; D M Dreon; R S Paffenbarger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1995 Oct-Nov       Impact factor: 4.254

4.  Mode of suppression of pituitary and gonadal function after acute or prolonged administration of a luteinizing hormone-releasing hormone antagonist in normal men.

Authors:  S N Pavlou; G Wakefield; N L Schlechter; J Lindner; K H Souza; T C Kamilaris; S Konidaris; J E Rivier; W W Vale; M Toglia
Journal:  J Clin Endocrinol Metab       Date:  1989-02       Impact factor: 5.958

5.  Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis.

Authors:  Peter Y Liu; Ronald S Swerdloff; Peter D Christenson; David J Handelsman; Christina Wang
Journal:  Lancet       Date:  2006-04-29       Impact factor: 79.321

6.  A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men.

Authors:  Yi-Qun Gu; Xing-Hai Wang; Dwo Xu; Lin Peng; Li-Fa Cheng; Ming-Kong Huang; Zhen-Jia Huang; Gui-Yuan Zhang
Journal:  J Clin Endocrinol Metab       Date:  2003-02       Impact factor: 5.958

7.  Contraceptive efficacy of a depot progestin and androgen combination in men.

Authors:  Leo Turner; Ann J Conway; Mark Jimenez; Peter Y Liu; Elise Forbes; Robert I McLachlan; David J Handelsman
Journal:  J Clin Endocrinol Metab       Date:  2003-10       Impact factor: 5.958

8.  5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males.

Authors:  R K Ross; L Bernstein; R A Lobo; H Shimizu; F Z Stanczyk; M C Pike; B E Henderson
Journal:  Lancet       Date:  1992-04-11       Impact factor: 79.321

9.  A clinical trial of 7 alpha-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men.

Authors:  Sigrid von Eckardstein; Gabriela Noe; Vivian Brache; Eberhard Nieschlag; Horacio Croxatto; Francisco Alvarez; Alfred Moo-Young; Irving Sivin; Narender Kumar; Margaret Small; Kalyan Sundaram
Journal:  J Clin Endocrinol Metab       Date:  2003-11       Impact factor: 5.958

10.  Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone.

Authors:  R S Swerdloff; C J Bagatell; C Wang; B D Anawalt; N Berman; B Steiner; W J Bremner
Journal:  J Clin Endocrinol Metab       Date:  1998-10       Impact factor: 5.958

View more
  22 in total

1.  Testin and actin are key molecular targets of adjudin, an anti-spermatogenic agent, in the testis.

Authors:  Dolores D Mruk; C Yan Cheng
Journal:  Spermatogenesis       Date:  2011-04

Review 2.  The roles of cyclic nucleotide phosphodiesterases (PDEs) in steroidogenesis.

Authors:  Li-Chun Lisa Tsai; Joseph A Beavo
Journal:  Curr Opin Pharmacol       Date:  2011-09-29       Impact factor: 5.547

Review 3.  Kinases as targets for chemical modulators: Structural aspects and their role in spermatogenesis.

Authors:  Pranitha Jenardhanan; Premendu P Mathur
Journal:  Spermatogenesis       Date:  2015-01-26

Review 4.  Effective Delivery of Male Contraceptives Behind the Blood-Testis Barrier (BTB) - Lesson from Adjudin.

Authors:  Haiqi Chen; Dolores D Mruk; Weiliang Xia; Michele Bonanomi; Bruno Silvestrini; Chuen-Yan Cheng
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

Review 5.  Male hormonal contraception: potential risks and benefits.

Authors:  Niloufar Ilani; Ronald S Swerdloff; Christina Wang
Journal:  Rev Endocr Metab Disord       Date:  2011-06       Impact factor: 6.514

6.  Spermiation: The process of sperm release.

Authors:  Liza O'Donnell; Peter K Nicholls; Moira K O'Bryan; Robert I McLachlan; Peter G Stanton
Journal:  Spermatogenesis       Date:  2011-01

7.  Acceptability of a transdermal gel-based male hormonal contraceptive in a randomized controlled trial.

Authors:  Mara Y Roth; Grace Shih; Niloufar Ilani; Christina Wang; Stephanie T Page; William J Bremner; Ronald S Swerdloff; Regine Sitruk-Ware; Diana L Blithe; John K Amory
Journal:  Contraception       Date:  2014-06-02       Impact factor: 3.375

8.  Male contraception: Where do we go from here?

Authors:  C Yan Cheng; Dolores D Mruk
Journal:  Spermatogenesis       Date:  2011-10-01

9.  Synthesis and evaluation of eight- and four-membered iminosugar analogues as inhibitors of testicular ceramide-specific glucosyltransferase, testicular β-glucosidase 2, and other glycosidases.

Authors:  Jae Chul Lee; Subhashree Francis; Dinah Dutta; Vijayalaxmi Gupta; Yan Yang; Jin-Yi Zhu; Joseph S Tash; Ernst Schönbrunn; Gunda I Georg
Journal:  J Org Chem       Date:  2012-03-20       Impact factor: 4.354

Review 10.  The blood-testis barrier and its implications for male contraception.

Authors:  C Yan Cheng; Dolores D Mruk
Journal:  Pharmacol Rev       Date:  2011-10-28       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.